Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Derek Tang

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Hemasphere|May 10, 2021
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA TrialRuben A Mesa, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Annals of Hematology|January 12, 2023
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST studyUlrich Germing, Pierre Fenaux, Uwe Platzbecker, et al.
Journal of Clinical Medicine|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 TrialEsther Natalie Oliva, Uwe Platzbecker, Guillermo Garcia-Manero, et al.
Hemasphere|May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 TrialClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Leukemia & Lymphoma|January 6, 2023
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registryRena Buckstein, Lisa Chodirker, Karen W L Yee, et al.
European Journal of Haematology|April 24, 2023
Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspaterceptMaria Domenica Cappellini, Ali T Taher, Antonio Piga, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 25, 2022
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease RegistryHans C Lee, Karthik Ramasamy, Katja Weisel, et al.
Leukemia & Lymphoma|September 12, 2022
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registryRena Buckstein, Lisa Chodirker, Lee Mozessohn, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Hemasphere|May 10, 2021
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA TrialRuben A Mesa, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Annals of Hematology|January 12, 2023
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST studyUlrich Germing, Pierre Fenaux, Uwe Platzbecker, et al.
Journal of Clinical Medicine|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 TrialEsther Natalie Oliva, Uwe Platzbecker, Guillermo Garcia-Manero, et al.
Hemasphere|May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 TrialClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Leukemia & Lymphoma|January 6, 2023
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registryRena Buckstein, Lisa Chodirker, Karen W L Yee, et al.
European Journal of Haematology|April 24, 2023
Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspaterceptMaria Domenica Cappellini, Ali T Taher, Antonio Piga, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 25, 2022
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease RegistryHans C Lee, Karthik Ramasamy, Katja Weisel, et al.
Leukemia & Lymphoma|September 12, 2022
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registryRena Buckstein, Lisa Chodirker, Lee Mozessohn, et al.
Pageof 4